Merck says his Covid antibody treatment is less effective than he originally thought

Merck Covid-19 oral treatment is not as effective as it once thought, the pharma team said Friday, after a thorough review of experimental results provided new results in reducing hospital mortality and mortality.

The company said its oral drug, molnupiravir, showed a 30 percent reduction in risk compared to placebo in all 1,400 patients enrolled in the trial. He also said last month that the decline was “about” 50 percent when it published basic information for a small number of patients.

In a complete study, one death was reported in the molnupiravir group, and nine in the placebo group.

Merck shares in New York lost 2.6 percent of the stock before a sell-off Friday, amid a massive market crash.

The company said the innovations continue to support “better monitoring and evaluation of the risk of molnupiravir by treating Covid-19 milder or lower in adults at high risk for the disease”. It also said it shared the supplement with the US Food and Drug Administration, which is reviewing the drug.

It also said that the number of success figures had already been met, and the external data agency advised them to stop enrolling in the study.

Molnupiravir, developed by Ridgeback Biotherapeutics and Lagevrio, has been approved for use in the UK. European observers are also under review. Merck has signed an agreement with the Medicines Patent Pool to make the drugs available to developing countries.